FRED HUTCHINSON CANCER CENTER
🇺🇸United States
Effects of Garlic Supplements on Drug Metabolism
Completed
- Conditions
- Healthy
- First Posted Date
- 2005-07-22
- Last Posted Date
- 2010-01-01
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 80
- Registration Number
- NCT00122889
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Health SMART (Stress Management and Relaxation Training) to Improve Vaccine Immune Response
Phase 1
Completed
- Conditions
- Psychological Stress
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2012-03-27
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 126
- Registration Number
- NCT00121160
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Promoting Activity and Changes in Eating (PACE) to Reduce Obesity
Not Applicable
Completed
- Conditions
- ObesityCardiovascular DiseasesHeart Diseases
- Interventions
- Behavioral: DietBehavioral: ExerciseBehavioral: Environment
- First Posted Date
- 2005-07-14
- Last Posted Date
- 2012-08-23
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 3000
- Registration Number
- NCT00119782
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 2
Terminated
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesChronic Myelomonocytic LeukemiaRecurrent Adult Acute Myeloid LeukemiaRefractory Anemia With Excess Blasts in TransformationAdult Acute Myeloid Leukemia With t(8;21)(q22;q22)Childhood Myelodysplastic SyndromesRecurrent Childhood Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Interventions
- Radiation: iodine I 131 monoclonal antibody BC8Radiation: total-body irradiationProcedure: allogeneic hematopoietic stem cell transplantationProcedure: peripheral blood stem cell transplantationOther: laboratory biomarker analysis
- First Posted Date
- 2005-07-13
- Last Posted Date
- 2022-12-12
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT00119366
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Fludarabine, Total-Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Chronic Myelogenous Leukemia
Phase 1
Completed
- Conditions
- Leukemia
- First Posted Date
- 2005-07-13
- Last Posted Date
- 2010-09-21
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 75
- Registration Number
- NCT00119340
- Locations
- 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸Veterans Affairs Medical Center - Seattle, Seattle, Washington, United States
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 2
Completed
- Conditions
- Recurrent Mantle Cell LymphomaB-cell Chronic Lymphocytic LeukemiaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Adult Grade III Lymphomatoid GranulomatosisRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Adult Lymphoblastic LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Adult Diffuse Mixed Cell Lymphoma
- Interventions
- Biological: rituximabRadiation: yttrium Y 90 ibritumomab tiuxetanProcedure: peripheral blood stem cell transplantationProcedure: allogeneic hematopoietic stem cell transplantationRadiation: total-body irradiation
- First Posted Date
- 2005-07-13
- Last Posted Date
- 2018-06-29
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 42
- Registration Number
- NCT00119392
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Ice Chips or Saline Mouth Rinse in Reducing or Preventing Mucositis in Patients Receiving Melphalan and Autologous Stem Cell Transplant for Multiple Myeloma
Not Applicable
Completed
- Conditions
- Multiple MyelomaPlasma Cell Neoplasm
- First Posted Date
- 2005-07-11
- Last Posted Date
- 2011-09-01
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 41
- Registration Number
- NCT00118339
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous Disease
Phase 1
Completed
- Conditions
- Kidney CancerLeukemiaLymphomaMyelodysplastic SyndromesNeuroblastomaSarcoma
- First Posted Date
- 2005-07-11
- Last Posted Date
- 2010-05-14
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00118326
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Azacitidine and Etanercept in Treating Patients With Myelodysplastic Syndromes
Phase 1
Completed
- Conditions
- de Novo Myelodysplastic SyndromesPreviously Treated Myelodysplastic SyndromesSecondary Myelodysplastic Syndromes
- Interventions
- Biological: etanercept
- First Posted Date
- 2005-07-11
- Last Posted Date
- 2017-05-24
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT00118287
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Phase 2
Completed
- Conditions
- Acute Undifferentiated LeukemiaAngioimmunoblastic T-cell LymphomaChildhood Acute Lymphoblastic Leukemia in RemissionHepatosplenic T-cell LymphomaMast Cell LeukemiaRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid LeukemiaRecurrent Adult Burkitt LymphomaAdult Acute Lymphoblastic Leukemia in RemissionAtypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
- Interventions
- Biological: alemtuzumabRadiation: total-body irradiationProcedure: allogeneic hematopoietic stem cell transplantationProcedure: peripheral blood stem cell transplantationBiological: graft versus host disease prophylaxis/therapyOther: laboratory biomarker analysis
- First Posted Date
- 2005-07-11
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT00118352
- Locations
- 🇮🇹
University of Torino, Torino, Italy
🇺🇸Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
© Copyright 2025. All Rights Reserved by MedPath